ClinicalTrialsFinder

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion

Sponsor

Bristol-Myers Squibb

Enrollment

260 participants

Start Date

Jul 27, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986504, a drug called Carboplatin, and others for people with solid tumors. The study is currently recruiting participants at 57 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986504

Specified dose on specified days

DRUGDaraxonrasib

Specified dose on specified days

DRUGNivolumab + Relatlimab FDC

Specified dose on specified days

DRUGTemozolomide

Specified dose on specified days

DRUGPumitamig

Specified dose on specified days

DRUGPemetrexed

Specified dose on specified days

DRUGCarboplatin

Specified dose on specified days

DRUGNab-paclitaxel

Specified dose on specified days

DRUGGemcitabine

Specified dose on specified days

DRUGPaclitaxel

Specified dose on specified days

Locations(57)

Local Institution - 0096

San Francisco, California, United States

Local Institution - 0182

Aurora, Colorado, United States

Local Institution - 0178

Atlanta, Georgia, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

Local Institution - 0124

Boston, Massachusetts, United States

Local Institution - 0119

Ann Arbor, Michigan, United States

Local Institution - 0129

Rochester, Minnesota, United States

Local Institution - 0174

Rochester, Minnesota, United States

Local Institution - 0181

Rochester, Minnesota, United States

Local Institution - 0142

Buffalo, New York, United States

Local Institution - 0170

New York, New York, United States

Local Institution - 0139

New York, New York, United States

Local Institution - 0100

Durham, North Carolina, United States

Local Institution - 0085

Houston, Texas, United States

Local Institution - 0086

Seattle, Washington, United States

Local Institution - 0134

Madison, Wisconsin, United States

Local Institution - 0148

Brussels, Bruxelles-Capitale, Région de, Belgium

Local Institution - 0114

Ghent, Oost-Vlaanderen, Belgium

Local Institution - 0051

Vancouver, British Columbia, Canada

Local Institution - 0021

Toronto, Ontario, Canada

Local Institution - 0007

Toronto, Ontario, Canada

Local Institution - 0155

Beijing, Beijing Municipality, China

Local Institution - 0185

Chongqing, Chongqing Municipality, China

Local Institution - 0184

Guangzhou, Guangdong, China

Local Institution - 0152

Xinxiang, Henan, China

Shanghai GoBroad Cancer Hospital China Pharmaceutical University

Shanghai, Shanghai Municipality, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Local Institution - 0078

Dijon, Côte-d'Or, France

Local Institution - 0075

Pierre-Bénite, Rhône, France

Local Institution - 0116

Villejuif, Val-de-Marne, France

Local Institution - 0074

Paris, France

Local Institution - 0081

Mainz, Rhineland-Palatinate, Germany

Local Institution - 0040

Hamburg, Germany

Local Institution - 0039

Heidelberg, Germany

Local Institution - 0061

Leipzig, Germany

Local Institution - 0049

München, Germany

Local Institution - 0047

Würzburg, Germany

Local Institution - 0150

Hksar, Hong Kong

Local Institution - 0063

Shatin, Hong Kong

Local Institution - 0080

Cork, Ireland

Local Institution - 0023

Dublin, Ireland

Local Institution - 0146

Dublin, Ireland

Local Institution - 0073

Siena, Tuscany, Italy

Local Institution - 0123

Bergamo, Italy

Local Institution - 0034

Milan, Italy

Local Institution - 0050

Naples, Italy

Local Institution - 0082

Perugia, Italy

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Local Institution - 0171

Bergen, Hordaland, Norway

Local Institution - 0022

Oslo, Norway

Local Institution - 0004

Seoul, Seoul-teukbyeolsi [Seoul], South Korea

Local Institution - 0058

Seoul, Seoul-teukbyeolsi [Seoul], South Korea

Local Institution - 0052

Seoul, Seoul-teukbyeolsi [Seoul], South Korea

Local Institution - 0068

Barcelona, Barcelona [Barcelona], Spain

Local Institution - 0071

Hospitalet, Barcelona [Barcelona], Spain

Local Institution - 0033

Madrid, Spain

Local Institution - 0069

Seville, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT07492680

Related Trials

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873780 locations

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

NCT0553614125 locations

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

NCT0691575316 locations

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031101 locations

A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

NCT072312111 location